Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$257.6 million.

  • Allogene Therapeutics' Net Income towards Common Stockholders rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
  • Per Allogene Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$257.6 million for FY2024, which was up 21.29% from -$327.3 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Net Income towards Common Stockholders peaked at -$250.2 million during FY2020, and registered a low of -$331.0 million during FY2022.
  • Over the past 3 years, Allogene Therapeutics' median Net Income towards Common Stockholders value was -$327.3 million (recorded in 2023), while the average stood at -$305.3 million.
  • Per our database at Business Quant, Allogene Therapeutics' Net Income towards Common Stockholders crashed by 35.55% in 2020 and then climbed by 21.29% in 2024.
  • Allogene Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$250.2 million in 2020, then decreased by 2.71% to -$257.0 million in 2021, then dropped by 28.78% to -$331.0 million in 2022, then grew by 1.12% to -$327.3 million in 2023, then climbed by 21.29% to -$257.6 million in 2024.